Jubilant Life Sciences’ material wholly-owned subsidiary ‘Jubilant Pharma’ (JPL), has received an approval to launch a benchmark offering of unsecured high yield bonds outside India, under Regulation S of the US Securities Act. The bonds are proposed to be listed on the Singapore Exchange Securities Trading. The board of directors at its meeting held on September 23, 2016 has approved for the same.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
